Ercem Atillasoy - Jan 18, 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Officer Title: Chief Regulatory and Safety Officer
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Stock symbol
ALVR
Transactions as of
Jan 18, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 04:24 PM
Previous filing
Oct 25, 2021
Next filing
Jan 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Award $0 +23.3K +23.18% $0.00 124K Jan 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALVR Stock Option (Right to Buy) Award $0 +56.7K $0.00 56.7K Jan 18, 2022 Common Stock 56.7K $9.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

Remarks:

Officer Title: Chief Regulatory and Safety Officer